Is pazopanib (Votrient) approved for the treatment of leiomyosarcoma? I believe it approved is for advanced renal cell carcinoma. —Elizabeth Greenberg, RN, ANP
Pazopanib (Votient) is an antineoplastic agent or tyrosine kinase inhibitor (TKI) that is currently approved for renal cell carcinoma, administered as an oral dose of 800 mg once daily.1 It is also indicated for advanced refractory soft tissue sarcoma (STS), administered in the same dose and frequency.2 Leiomyosarcoma is a soft tissue sarcoma that arises from smooth muscle cells. Off-label or unlabeled use reported was for the treatment of advanced differentiated thyroid cancer.3 —Abimbola Farinde, PharmD, MS, BCPP, CGP, LCDC, PM/PRC, FASCP, FACA, FNAP, Rsci, ARSPharmS
1. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-068.
2. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-1886.
3. Votrient. Lexicomp Web site. http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/2005522.